How are you approaching multidisciplinary care for patients with newly diagnosed BCG-naive high-risk NMIBC in light of POTOMAC?
Who is overseeing the administration and follow up of checkpoint inhibitor therapy in your practice (urology or medical oncology or both?)
Community PollStarted
Who oversees administration and follow-up of durvalumab in BCG-naive high-risk NMIBC patients in your practice?
12 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Urology · University of Washington School of Medicine
Answered on
We have not incorporated BCG-naïve high-risk NMIBC patients into our Bladder Cancer Multidisciplinary Clinic workflows to date. That being said, we are discussing including a subset of high-risk patients in our Multidisciplinary Clinic as we incorporate the POTOMAC results into our workflows. In our...
Join for free or sign in to see the full answer
Mednet Member
Medical Oncology · University of California Los Angeles, Los Angeles
Answered on
The POTOMAC trial is reinforcing the need for multidisciplinary care for patients with newly diagnosed BCG-naive high-risk NMIBC who will be treated with durvalumab and BCG. Given that the medical oncologists have years of experience in delivering systemic chemotherapy and specifically immunotherapy...
Join for free or sign in to see the full answer